ClinicalTrials.gg
Active, not recruitingNCT04809714Updated Jan 26, 2026

The Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture

An interventional study of Blood Flow Restriction with Delfi Tourniquet System Cuff and Routine Post-operative Physical Therapy in Hip Fractures and Muscle Atrophy, sponsored by University of Alabama at Birmingham. Active, not recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Hip Fractures with a site in United States — 22 open to participants now, 31 under way, none of them phase 3. Hip Fractures · United States.

Enrollment
81st of 105
20 · median 64
Started
2022
with 6 others
No phase
62 of 133
13 open now
Primary completion
2026-12
later than 3 of 30 live
Registered
97th of 133
by date

Among the 133 studies in Hip Fractures with a site in United States, this one is the 81st largest by enrollment of the 105 interventional ones that give a count, is one of 7 that started in 2022, is one of 62 with no phase, reaches primary completion later than 3 of the 30 other live ones, and was the 97th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

22 of the 133 studies in Hip Fractures with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Hip Fractures with a site in United States, or all of them as a file.
02

Study summary

The investigators aim to study the use of blood flow restriction therapy (BFR) to augment routine post-operative physical therapy in elderly patients (age >= 65) after recovering from surgical treatment of hip fractures.

Read the detailed description

For elderly patients, a hip fracture is a life-altering event associated with poor overall outcomes despite early surgical treatment. The elderly population and those with significant osteopenia is growing exponentially and thus the optimal treatment and rehabilitation of hip fractures warrants increased investigation. Despite numerous interventions, falls plague the elderly population and hip fractures remain a very common problem for this population that needs to be addressed. Rapid deconditioning plays a significant role in patient morbidity following hip surgery. Recently, blood flow restriction (BFR) treatment has been shown to be effective in improving muscle strength when combined with low load resistance training physical therapy programs in elderly patients. Few studies have examined BFR in post-operative orthopedic trauma patients. The investigators aim to study the use of BFR to augment post-operative physical therapy in elderly patients (age >= 65) in the first 2-weeks after recovering from surgical treatment of hip fractures. Due to the profound muscle atrophy that occurs in the immediate postoperative period because of immobility and disuse, the investigators hypothesize that BFR may provide an anabolic effect and conserve muscle strength. The investigators hypothesis was inspired by the findings of the Nobel Prize in Physiology 2019 which describes how varying levels of oxygen shape both physiology and pathology. This is a prospective, randomized blinded 2-week study of elderly patients recovering from surgical treatment of hip fractures with two arms: 1) routine post-op physical therapy 2) routine physical therapy + BFR and neuromuscular electrical stimulation (NMES) beginning on postoperative day 1 and occurring 5 days per week for 2 weeks. To optimize safety, the study will be in an inpatient-only setting and supervised by team members certified in the application of BFR. The investigators plan to apply lessons learned to a larger 8-week intervention upon completion of this short-term pilot study. To our knowledge, this is the first study to use BFR in postoperative geriatric patients. Main outcomes will include thigh leg circumference on postoperative day 1 and at the end of week 2, adverse event log for complications, knee extension strength via handheld dynamometry (HHD) at post-op day 1 and week 2, gait speed, functional tests including timed up and go, opioid MME (morphine milligram equivalent) consumption and patient perceived pain and quality of life measures. The investigators anticipate BFR therapy will be tolerated well, improve global patient health and satisfaction, lead to lower extremity muscle hypertrophy, and enhance functional recovery after geriatric hip fracture carrying tremendous potential for extramural funding and scientific advancement.

03

Conditions studied

  • Hip Fractures
  • Muscle Atrophy

Keywords

  • Hip Surgery
  • Geriatric
  • Blood flow restriction therapy
  • Muscle atrophy
  • Muscle disuse
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 65 years old, any sex, any ethnicity
  • Isolated, closed proximal femur fracture without any prior surgery or orthopedic implants to affected proximal femur. This includes all fractures with primary fracture line that is proximal to the lesser trochanter. For example, subtrochanteric femur fractures are excluded whereas reverse obliquity intertrochanteric femur fractures may be included.
  • OTA codes 31A, 31B, and 31C
  • Segmental and pathologic femur fractures are excluded.
  • Ambulatory without assistive device prior to injury
  • Community living prior to injury
  • No injury or surgery to the contralateral lower extremity within past 1 year
  • Alert and oriented and able to provide for self
  • English speaking
  • Able to weight bear as tolerated after surgery as deemed by treating orthopedic surgeon
  • Able to tolerate light exercise (could walk approximately 0.5 mile without significant pain or shortness of breath) preoperatively as determined by patient self-reported history

Exclusion criteria

Exclusion Criteria:

  • Presence of other significant injuries at the time of injury to the proximal femur that would require additional surgery
  • Significant delay in presentation to health care facility (>3 days from time of injury) for assessment and treatment of the proximal femur fracture
  • History of DVT in any extremity, existing DVT in any extremity, or any condition known to increase risk for coagulopathy including but not exclusively current pregnancy, current diagnosis of cancer/cancer that is being treated
  • Current use of any medication or supplement that may increase blood clotting risk
  • History of: sickle cell anemia, peripheral arterial disease, dementia, actively treated cancer
  • Varicose veins in either lower extremity
  • Any significant medical condition that would preclude ability to bear weight as tolerated postoperatively
  • Significant cardiac disease as defined by recent stent placement in the past year or presence of implantable pacemaker device
  • Morbid obesity ( >40)
  • Prior surgery to either lower extremity within one year
  • Prior surgery or injury to either lower extremity that would preclude application of a tourniquet and includes but not exclusively: skin grafting, vascular bypass grafting, dialysis site, chronic wound, lymphotomies, varicose vein surgery, presence of tumor)
  • Soft tissue injury to either lower extremity that precludes placement of tourniquet
  • Diagnosis of uncontrolled hypertension (BP greater than 180/110 on at least two measurements as measured during inpatient stay before surgery)
  • Patients with potentially severe problems with maintaining follow-up (ex. Patients who are prisoners, homeless at time of injury, severe dementia, intellectually challenged without adequate family support or have documented significant psychiatric disorder)
  • COVID-19 positive
  • Admission to ICU postoperatively
  • Inadequate postop x-rays placing patient at high risk of implant-related failure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Routine Post-operative Physical Therapy

    The control group will undergo routine post-op and undergo a modified version of the graduated therapy protocol.

    Other: Routine Post-operative Physical Therapy

  • Experimental
    Routine Physical Therapy + Blood Flow Restriction and Neuromuscular Electrical Stimulation (NMES)

    The intervention group will start with a Delfi tourniquet system cuff set on a limb occlusion pressure (LOP) of 60-100%. The intervention group will also use a neuromuscular electrical stimulation device at therapeutic level in addition to BFR.

    Device: Blood Flow Restriction with Delfi Tourniquet System Cuff

Interventions

  • DeviceBlood Flow Restriction with Delfi Tourniquet System Cuff

    Postoperative rehabilitation will occur up to twice a day for 5 days a week for 2 weeks using a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of 60-100%. For each physical therapy session, participants will undergo therapy following a standardized protocol of 3-5 difference exercises each with 4 sets total in addition to NMES.

  • OtherRoutine Post-operative Physical Therapy

    The control group with undergo a post-op therapy protocol that mirrors that of the intervention group except that they will use a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of only 10%. Participants will use a neuromuscular electrical stimulation device operating at a sub-therapeutic level.

06

What researchers measure

Primary outcomes

  1. Participants thigh circumference measurement

    10cm proximal to superior pole patella and leg circumference measured at 10 distal to inferior pole patella for both extremities

    Time frame: At enrollment

  2. Participants thigh circumference measurement

    10cm proximal to superior pole patella and leg circumference measured at 10 distal to inferior pole patella for both extremities

    Time frame: Post op 2 weeks

  3. Therapist-reported compliance and adverse event logs

    Specify if able to perform specific exercises to completion or not

    Time frame: Post op 2 weeks

  4. Objective muscle strength measured by a handheld dynamometer

    To assess strength of quadriceps extension

    Time frame: At enrollment

  5. Objective muscle strength measured by a handheld dynamometer

    To assess strength of quadriceps extension

    Time frame: Post op 2 weeks

  6. Participant self-reported outcome for pain

    The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain." The range of scores are from 0-100. A higher score indicates greater pain intensity.

    Time frame: Post op 2 weeks

  7. Participant self-reported outcome: Perceived Exertion (Borg Rating of Perceived Exertion)

    To assess effort and exertion, breathlessness and fatigue during exercise

    Time frame: Post op 2 weeks

Secondary outcomes

  1. Timed Up and Go Test (TUG)

    Measurement of the time in seconds for a person to rise from sitting from a standard arm chair, walk 3 meters, walk back to the chair, and sit down.

    Time frame: Post op 2 weeks

  2. Modified 30-second sit-to-stand test

    Measurement of the number of sit-to-stands a person can complete in 30 seconds.

    Time frame: Post op 2 weeks

  3. Five-times sit to stand test

    Measures lower extremity strength and function. Participants are asked to stand up from a seated position and sit down 5 times as quickly as possible.

    Time frame: Post op 2 weeks

  4. Functional testing performed

    5 Meter gait speed test

    Time frame: Post op 2 weeks

  5. 12-Item Short Form Health Survey (SF-12) (Mental Health Component)

    This is a general health questionnaire with higher scores representing better health. A summary score from the SF-12 (Mental Health Component) will be reported. The score may be represented as a Z-score. The average summary score is 50 points with a standard deviation of 10 points.

    Time frame: Post op 2 weeks

  6. 12-Item Short Form Health Survey (SF-12) (Physical Health Component)

    This is a general health questionnaire with higher scores representing better health. A summary score from the SF-12 (Physical Health Component) will be reported. The score may be represented as Z-score. The average of the summary score is 50 points with a standard deviation of 10 points.

    Time frame: Post op 2 weeks

  7. Patient-Reported Outcomes Measurement Information System (PROMIS)

    This questionnaire measures physical, mental, and social health. Higher scores represents more of the concept being measured. A score of 40 is one standard deviation lower than the mean of the reference population while a score of 60 is one standard deviation higher than the mean of the reference population.

    Time frame: Post op 2 weeks

  8. Pain medicine requirements during 2-week stay

    To assess the milligram morphine equivalents of pain medicine used.

    Time frame: Post op 2 weeks

Other outcomes

  1. Post-operative complications: Mortality

    Mortality will be assessed by living status.

    Time frame: Post op 2 weeks

  2. Post-operative complications: Blood Clots

    Blood clots will be assessed by a detailed physical examination.

    Time frame: Post op 2 weeks

  3. Post-operative complications: Deep Infection

    Deep infection will be assessed by the need to return to the operating room for surgical debridement or by the presence of positive cultures.

    Time frame: Post op 2 weeks

  4. Post-operative complications: Nerve Damage

    Nerve damage will be assessed by a detailed physical examination assessing both sensory and motor functions.

    Time frame: Post op 2 weeks

  5. Number of patient-reported falls

    To assess tolerance of BFR we will record the incidence of falls.

    Time frame: Post op 2 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Prabhakar NR. 2019 Nobel Prize in Physiology or Medicine. Physiology (Bethesda). 2020 Mar 1;35(2):81-83. doi: 10.1152/physiol.00001.2020. No abstract available. PubMed 32024429 ↗
  • Bhandari M, Devereaux PJ, Swiontkowski MF, Tornetta P 3rd, Obremskey W, Koval KJ, Nork S, Sprague S, Schemitsch EH, Guyatt GH. Internal fixation compared with arthroplasty for displaced fractures of the femoral neck. A meta-analysis. J Bone Joint Surg Am. 2003 Sep;85(9):1673-81. doi: 10.2106/00004623-200309000-00004. PubMed 12954824 ↗
  • Simunovic N, Devereaux PJ, Sprague S, Guyatt GH, Schemitsch E, Debeer J, Bhandari M. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ. 2010 Oct 19;182(15):1609-16. doi: 10.1503/cmaj.092220. Epub 2010 Sep 13. PubMed 20837683 ↗
  • Baker BS, Stannard MS, Duren DL, Cook JL, Stannard JP. Does Blood Flow Restriction Therapy in Patients Older Than Age 50 Result in Muscle Hypertrophy, Increased Strength, or Greater Physical Function? A Systematic Review. Clin Orthop Relat Res. 2020 Mar;478(3):593-606. doi: 10.1097/CORR.0000000000001090. PubMed 31860546 ↗
  • Bowman EN, Elshaar R, Milligan H, Jue G, Mohr K, Brown P, Watanabe DM, Limpisvasti O. Proximal, Distal, and Contralateral Effects of Blood Flow Restriction Training on the Lower Extremities: A Randomized Controlled Trial. Sports Health. 2019 Mar/Apr;11(2):149-156. doi: 10.1177/1941738118821929. Epub 2019 Jan 14. PubMed 30638439 ↗
  • Centner C, Wiegel P, Gollhofer A, Konig D. Effects of Blood Flow Restriction Training on Muscular Strength and Hypertrophy in Older Individuals: A Systematic Review and Meta-Analysis. Sports Med. 2019 Jan;49(1):95-108. doi: 10.1007/s40279-018-0994-1. PubMed 30306467 ↗
  • Natsume T, Ozaki H, Saito AI, Abe T, Naito H. Effects of Electrostimulation with Blood Flow Restriction on Muscle Size and Strength. Med Sci Sports Exerc. 2015 Dec;47(12):2621-7. doi: 10.1249/MSS.0000000000000722. PubMed 26110693 ↗

Individual participant data

Plan to share: No — To be determined.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2026, 59 months after the start.

Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 59 months is above that.

Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2021
First posted
Mar 22, 2021
StartActual
Jan 1, 2022
Primary completionEst.
Dec 13, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04809714
Responsible party
Clay Spitler (Principle Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Mar 22, 2021
Start date
Jan 1, 2022
Primary completion
Dec 13, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 26, 2026

Study contacts

David A Patch, MD
study director · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion